E-LIB Suche - Ergebnisse für: Wise, Mark G G

1

Global trends in carbapenem- and difficult-to-treat-resista..:

Wise, Mark G. ; Karlowsky, James A. ; Mohamed, Naglaa...
Journal of Global Antimicrobial Resistance. 37 (2024) - p. 168-175 , 2024

Link: https://doi.org/10.1016/..

2

Susceptibility of gram-negative isolates collected in Taiwa..:

Wise, Mark G. ; Karlowsky, James A. ; Chen, Wei-Ting...
Journal of the Formosan Medical Association. 123 (2024) 3 - p. 400-407 , 2024

Link: https://doi.org/10.1016/..

3

2153. Addition of Relebactam Increases Susceptibility to Im..:

Lob, Sibylle ; Wise, Mark G ; Chen, Wei-Ting...
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

4

Epidemiology and in vitro activity of ceftazidime-avibactam..:

Wise, Mark G. ; Karlowsky, James A. ; Lemos-Luengas, Elkin V...
The Brazilian Journal of Infectious Diseases. 27 (2023) 3 - p. 102759 , 2023

Link: https://doi.org/10.1016/..

5

Incidence of ESBLs and carbapenemases among Enterobacterale..:

Gales, Ana C ; Stone, Gregory ; Sahm, Daniel F..
Journal of Antimicrobial Chemotherapy. 78 (2023) 7 - p. 1606-1615 , 2023

Link: https://doi.org/10.1093/..

6

2150. In Vitro Activity of Cefepime-Taniborbactam and Compa..:

Wise, Mark G ; Hackel, Meredith ; Sahm, Daniel F
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

7

2155. Low prevalence of OXA-48-like carbapenemases and susc..:

Lob, Sibylle ; Wise, Mark G ; Siddiqui, Fakhar...
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

8

In vitro activity of aztreonam–avibactam against Enterobact..:

Wise, Mark G. ; Karlowsky, James A. ; Mohamed, Naglaa..
European Journal of Clinical Microbiology & Infectious Diseases. 42 (2023) 9 - p. 1135-1143 , 2023

Link: https://doi.org/10.1007/..

9

Temporal and geographical prevalence of carbapenem-resistan..:

Karlowsky, James A. ; Wise, Mark G. ; Hsieh, Tai-Chin...
Journal of Global Antimicrobial Resistance. 34 (2023) - p. 106-112 , 2023

Link: https://doi.org/10.1016/..

10

2154. Cross-resistance of Ceftolozane-Tazobactam and Imipen..:

Lob, Sibylle ; Wise, Mark G ; Bauer, Karri...
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

11

In vitro activity of cefiderocol against MBL-producing Gram..:

Takemura, Miki ; Wise, Mark G ; Hackel, Meredith A..
Journal of Antimicrobial Chemotherapy. 78 (2023) 8 - p. 2019-2027 , 2023

Link: https://doi.org/10.1093/..

12

In vitro activity of ceftazidime-avibactam against clinical..:

Wise, Mark G. ; Karlowsky, James A. ; Hackel, Meredith A....
Journal of Global Antimicrobial Resistance. 35 (2023) - p. 93-100 , 2023

Link: https://doi.org/10.1016/..

13

2129. Antimicrobial Activity of Cefepime in Combination wit..:

Hackel, Meredith ; Wise, Mark G ; Sahm, Daniel F
Open Forum Infectious Diseases. 10 (2023) Supplement_2 - p. , 2023

Link: https://doi.org/10.1093/..

14

In VitroActivity of Cefepime-Taniborbactam and Comparators ..:

Karlowsky, James A. ; Hackel, Meredith A. ; Wise, Mark G....
Antimicrobial Agents and Chemotherapy. 67 (2023) 1 - p. , 2023

Link: https://doi.org/10.1128/..

15

Susceptibility of Gram-negative isolates collected in South..:

Karlowsky, James A ; Wise, Mark G ; Chen, Wei-Ting...
JAC-Antimicrobial Resistance. 6 (2023) 1 - p. , 2023

Link: https://doi.org/10.1093/..